Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 78 of 78 results for psoriasis

  1. Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)

    Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.

    Technology appraisal guidance
    Published
    6 December 2023
    View recommendations

    Sections for TA935

  2. Subcutaneous spesolimab 1 ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over [ID6216]

    In development Reference number: GID-TA11189 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Digital technologies for the detection of melanoma (MIB311)

    NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .

    Medtech innovation briefing
    Published
    1 November 2022